Glaukos
Glaukos Corporation, a pioneering force in the ophthalmic industry, is headquartered in the United States, with significant operations across North America and Europe. Founded in 1998, Glaukos has established itself as a leader in developing innovative therapies for glaucoma and other eye diseases. The company is renowned for its unique micro-invasive surgical procedures, particularly the iStent® technology, which has transformed the treatment landscape for patients suffering from glaucoma. With a commitment to advancing eye care, Glaukos has achieved notable milestones, including the first FDA approval of a micro-invasive glaucoma surgery device. The company’s dedication to research and development has positioned it at the forefront of the ophthalmic market, making significant contributions to improving patient outcomes and enhancing the quality of life for those affected by vision-related conditions.
DitchCarbon Score
How does Glaukos's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Glaukos's score of 28 is higher than 93% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Glaukos's reported carbon emissions
In 2022, Glaukos reported total emissions of approximately 1,916,600 kg CO2e, comprising 569,400 kg CO2e from Scope 1 and 1,360,200 kg CO2e from Scope 2 emissions. The company has set ambitious climate commitments, aiming to reduce its Scope 1 and Scope 2 emissions to near zero by 2025. This initiative reflects Glaukos's dedication to sustainability and aligns with industry standards for climate action. The company is actively working towards these targets, demonstrating a proactive approach to mitigating its carbon footprint in the medical technology sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | |
|---|---|
| Scope 1 | 569,400 |
| Scope 2 | 1,360,200 |
| Scope 3 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Glaukos is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
